Intercept Q1 results

Intercept Pharmaceuticals (ICPT -2.4%) licensing revenue: $405K (unch); operating loss: ($31.2M) (-358.8%); net loss: ($257.7M) (-2,426%); quick assets: $134.1M (-7.4%).

All outstanding warrants as of quarter end converted to 834,758 common shares on April 10 generating $56M in non-cash income for Q2.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs